The comparison of long-acting GLP-1 receptor agonist liraglutide or selective PDE4 inhibitor roflumilast versus metformin on changes of measures of obesity have not yet been evaluated in women with PCOS or any other obese population. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.